infliximab - Clinical Research Society

J&J’s Remicade Backed by FDA Committee for Approval in Pediatrics

0 Comments infliximab, Johnson & Johnson, Remicade

Earlier on Thursday, Johnson & Johnson’s Remicade (infliximab), which is administered to pediatric patients with moderately to severely active ulcerative

Offer the visitors your services or goods.

Describe what they will receive and how they will benefit from it.